The company said Dr. Sylvie Grégoire, a member of its Board of Directors, notified it that she will not stand for re-election at the annual meeting of shareholders scheduled for January 25, 2024 April 23, 2024.

1. 01

   The company said Dr. Sylvie Grégoire, a member of its Board of Directors, notified it that she will not stand for re-election at the annual meeting of shareholders scheduled for January 25, 2024 April 23, 2024.

2. 02

   The company said Dr. Grégoire's decision not to stand for re-election is not due to any disagreement between her and the company over its operations, policies or practices.

3. 03

   The company said its Board elected Michael A. Klobuchar and Sophie V. Vandebroek as directors on January 25, 2024, effective February 1, 2024, and that neither will serve on a Board committee upon election.

4. 04

   The company said each of the two new directors will receive a stock award of Revvity common stock with a fair market value of $22,500 and a grant of restricted stock units with a fair market value of $27,500, representing the annual equity compensation for non-employee directors, prorated for the remaining portion of the Board service year. It said each director will also be eligible to be paid the annual cash retainer for non-employee directors of $90,000, also prorated.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.